Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.

Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 10; 20(5):724-735.

View in: PubMed

subject areas

Acute Coronary Syndrome
Aspirin
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Humans
Molecular Diagnostic Techniques
Platelet Aggregation Inhibitors
Predictive Value of Tests
Quality-Adjusted Life Years
Time Factors
Treatment Outcome

authors with profiles

Vakaramoko Diaby

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support